JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO)

JPMorgan Chase & Co. lifted its stake in shares of Korro Bio, Inc. (NASDAQ:KRRO - Free Report) by 374.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,391 shares of the company's stock after purchasing an additional 9,782 shares during the quarter. JPMorgan Chase & Co. owned 0.13% of Korro Bio worth $414,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Quest Partners LLC lifted its stake in Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company's stock worth $59,000 after purchasing an additional 1,124 shares during the last quarter. Brown Brothers Harriman & Co. raised its holdings in shares of Korro Bio by 251.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company's stock worth $95,000 after buying an additional 2,041 shares in the last quarter. Vestcor Inc bought a new stake in shares of Korro Bio during the 3rd quarter worth $100,000. MetLife Investment Management LLC boosted its stake in Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock valued at $122,000 after buying an additional 2,050 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Korro Bio by 1,018.2% in the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company's stock valued at $164,000 after acquiring an additional 4,470 shares during the last quarter. Institutional investors own 13.18% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KRRO. Oppenheimer began coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an "outperform" rating and a $155.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $115.00 price objective on shares of Korro Bio in a report on Friday, November 22nd. Raymond James initiated coverage on shares of Korro Bio in a research report on Monday, October 21st. They issued a "strong-buy" rating and a $153.00 price target for the company. William Blair reissued an "outperform" rating on shares of Korro Bio in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada raised their target price on Korro Bio from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Monday, October 21st. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Korro Bio currently has a consensus rating of "Buy" and a consensus price target of $144.00.

Korro Bio Stock Performance

Shares of KRRO stock traded up $1.09 during mid-day trading on Thursday, hitting $34.18. The company's stock had a trading volume of 63,424 shares, compared to its average volume of 90,585. Korro Bio, Inc. has a 52 week low of $30.00 and a 52 week high of $98.00. The company's fifty day simple moving average is $42.69 and its 200-day simple moving average is $45.88.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, topping analysts' consensus estimates of ($2.55) by $0.29. As a group, equities research analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Insider Transactions at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the company's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.40% of the company's stock.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).